Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RANDOMISED, CONTROLLED STUDY WITH A BLINDED END-POINT TO EVALUATE BY MEANS OF 24-HOUR AMBULATORY BLOOD PRESSURE MONITORING THE ANTIHYPERTENSIVE ACTIVITY OF OLMESARTAN 20 MG IN COMPARISON WITH THAT OF VALSARTAN 160 MG, AND THEIR COMBINATION WITH HYDROCHLOROTIAZIDE IN PATIENTS WITH MODERATE ARTERIAL HYPERTENSION WITH ANOTHER CARDIOVASCULAR RISK FACTOR..

Trial Profile

RANDOMISED, CONTROLLED STUDY WITH A BLINDED END-POINT TO EVALUATE BY MEANS OF 24-HOUR AMBULATORY BLOOD PRESSURE MONITORING THE ANTIHYPERTENSIVE ACTIVITY OF OLMESARTAN 20 MG IN COMPARISON WITH THAT OF VALSARTAN 160 MG, AND THEIR COMBINATION WITH HYDROCHLOROTIAZIDE IN PATIENTS WITH MODERATE ARTERIAL HYPERTENSION WITH ANOTHER CARDIOVASCULAR RISK FACTOR..

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 May 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olmesartan medoxomil (Primary) ; Hydrochlorothiazide; Valsartan
  • Indications Essential hypertension
  • Focus Therapeutic Use

Most Recent Events

  • 23 May 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top